Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FZ-AD004 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FZ AD004 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Most Recent Events

16 May 2024 Status changed from not yet recruiting to recruiting.
30 Jun 2023 New trial record
18 Jan 2023 According to a Shanghai Fosun Pharmaceutical Development media release, the company has received Acceptance Notice (Acceptance No. CXSL2300047) by the National Medical Products Administration of the PRC for investigational new drug application for Phase I clinical trial of FZ-AD004 antibody drug conjugate for injection for the treatment of advanced solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com